

Mediclinic International plc  
 (Incorporated in England and Wales)  
 Company Number: 08338604  
 LSE Share Code: MDC  
 JSE Share Code: MEI  
 NSX Share Code: MEP  
 ISIN: GB00B8HX8Z88  
 LEI: 2138002S5BSBIZTD5160  
 South African income tax number: 9432434182  
 ('Mediclinic', the 'Company', or the 'Group')

29 July 2022

## ANNOUNCEMENT OF THE 2022 ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its annual general meeting ('AGM') held on 28 July 2022, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

		Total shares voted	% of issued share capital voted	Votes for	%	Votes against	%	Votes withheld
	<b>Ordinary resolutions</b>							
1.	To receive the Company's annual accounts and reports	596,970,568	80.97%	596,967,610	100.00%	2,958	0.00%	1,159,715
2.	To approve the Directors' Remuneration Report	598,012,431	81.11%	589,896,604	98.64%	8,115,827	1.36%	117,852
3.	To approve the Directors' Remuneration Policy	598,012,550	81.11%	569,202,418	95.18%	28,810,132	4.82%	117,733
4.	To approve the Mediclinic International plc 2022 Omnibus Share Plan	598,010,573	81.11%	573,537,947	95.91%	24,472,626	4.09%	119,710
5.	To Declare a final cash dividend of 3.00 pence per Ordinary share	598,014,831	81.11%	597,924,068	99.98%	90,763	0.02%	115,452
6.	To elect Natalia Barsegiyan as a director	598,014,131	81.11%	597,690,478	99.95%	323,653	0.05%	116,152
7.	To elect Zarina Bassa as a director	598,014,131	81.11%	592,837,220	99.13%	5,176,911	0.87%	116,152
8.	To re-elect Dame Inga Beale as a director	598,007,131	81.11%	575,287,610	96.20%	22,719,521	3.80%	123,152
9.	To re-elect Dr Ronnie van der Merwe as a director	598,014,131	81.11%	594,837,854	99.47%	3,176,277	0.53%	116,152
10.	To re-elect Mr Jurgens Myburgh as a director	598,012,731	81.11%	596,892,792	99.81%	1,119,939	0.19%	117,552
11.	To re-elect Dr Felicity Harvey as a director	598,013,056	81.11%	594,931,716	99.48%	3,081,340	0.52%	117,227

		<b>Total shares voted</b>	<b>% of issued share capital voted</b>	<b>Votes for</b>	<b>%</b>	<b>Votes against</b>	<b>%</b>	<b>Votes withheld</b>
12.	To re-elect Dr Muhadditha Al Hashimi as a director	598,014,156	81.11%	597,020,547	99.83%	993,609	0.17%	116,127
13.	To re-elect Mr Jannie Durand as a director	598,014,455	81.11%	578,345,293	96.71%	19,669,162	3.29%	115,828
14.	To re-elect Mr Danie Meintjes as a director	598,014,876	81.11%	577,405,360	96.55%	20,609,516	3.45%	115,407
15.	To re-elect Dr Anja Oswald as a Director	598,013,056	81.11%	594,929,929	99.48%	3,083,127	0.52%	117,227
16.	To re-elect Mr Tom Singer as a director	598,013,056	81.11%	596,945,928	99.82%	1,067,128	0.18%	117,227
17.	To re-elect Mr Steve Weiner as a director	598,013,056	81.11%	596,945,928	99.82%	1,067,128	0.18%	117,227
18.	To re-appoint PricewaterhouseCoopers LLP as the Company's auditor	598,015,580	81.12%	590,295,042	98.71%	7,720,538	1.29%	114,703
19.	To authorise the Audit and Risk Committee to determine the auditor's remuneration	598,014,245	81.11%	597,986,286	100.00%	27,959	0.00%	116,038
20.	To authorise political donations	597,929,253	81.10%	498,464,252	83.37%	99,465,001	16.63%	201,030
21.	To authorise the directors to allot ordinary shares	598,012,401	81.11%	457,826,531	76.56%	140,185,870	23.44%	117,882
	<b>Special resolutions</b>							
22.	To authorise the directors to dis-apply statutory pre-emption rights	597,972,551	81.11%	542,361,185	90.70%	55,611,366	9.30%	157,732
23.	To authorise the directors to dis-apply pre-emption rights for purposes of acquisitions or capital investments	597,972,101	81.11%	543,889,553	90.96%	54,082,548	9.04%	158,182
24.	To approve the reduction in minimum notice period for general meetings (other than annual general meetings)	598,013,838	81.11%	571,047,986	95.49%	26,965,852	4.51%	116,445

**Votes of shareholders excluding the controlling shareholder on election and re-election of independent non-executive directors**

	Ordinary Resolutions	Total shares voted	% of issued share capital voted	Votes for	%	Votes against	%	Votes withheld
6.	To elect Natalia Barsegiyan as a director	269,516,243	65.94%	269,192,590	99.88%	323,653	0.12%	116,152
7.	To elect Zarina Bassa as a director	269,516,243	65.94%	264,339,332	98.08%	5,176,911	1.92%	116,152
8.	To re-elect Dame Inga Beale as a director	269,509,243	65.94%	246,789,722	91.57%	22,719,521	8.43%	123,152
11.	To re-elect Dr Felicity Harvey as a director	269,515,168	65.94%	266,433,828	98.86%	3,081,340	1.14%	117,227
12.	To re-elect Dr Muhadditha Al Hashimi as a director	269,516,268	65.94%	268,522,659	99.63%	993,609	0.37%	116,127
15.	To re-elect Dr Anja Oswald as a Director	269,515,168	65.94%	266,432,041	98.86%	3,083,127	1.14%	117,227
16.	To re-elect Mr Tom Singer as a director	269,515,168	65.94%	268,448,040	99.60%	1,067,128	0.40%	117,227
17.	To re-elect Mr Steve Weiner as a director	269,515,168	65.94%	268,448,040	99.60%	1,067,128	0.40%	117,227

**Notes:**

- Any proxy appointments giving discretion to the Chair of the meeting have been included in the "For" total.
- A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
- The Company's total ordinary shares in issue (total voting rights) as at 28 July 2022 was 737 243 810 shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.
- As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules ('Listing Rules'), each resolution to elect an independent non-executive director (Resolutions 6, 7, 8, 11, 12, 15, 16 and 17) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by: (a) the shareholders of the Company as a whole; and (b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

**Statement regarding voting results**

The Board notes that while Resolution 21 was passed with a majority of 76.56%, as in previous years, a number of our shareholders opposed this resolution.

The views of all shareholders are important to the Board. The Company will reflect carefully on the feedback already received on this matter and continue to engage with shareholders, to ensure its understanding of their views and Mediclinic will publish an update on that engagement within six months of the AGM.

In the interim, the Board notes that, the voting outcome on Resolution 21 reflects the prevailing institutional voting policies in South Africa. As a company with a primary premium listing on the London Stock Exchange ('LSE'), the Board considers it appropriate to seek authorities in line with the UK Investment Association's Share Capital Management Guidelines, which provide the Company with greater flexibility to respond to market developments and business opportunities as they arise. Many of the Group's South African institutional investors understand the Company's position but some operate under

mandates that do not allow them to support this level of flexibility. Mediclinic will continue to engage with its South African shareholders on this topic; however in view of the marked differences between UK and South African market practice in this area, it is likely that there will continue to be significant votes against this resolution.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the AGM has been submitted to the National Storage Mechanism and is available for inspection at:

<https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company's website at <https://investor.mediclinic.com/regulatory-news>.

### **About Mediclinic International plc**

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 22 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 22 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom ('UK'), with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the UK and listed on the LSE.

For further information, please contact:

#### **Company Secretary, Link Company Matters Limited**

Caroline Emmet

+44 (0)333 300 1930

#### **Investor queries**

James Arnold, Head of Investor Relations

[ir@mediclinic.com](mailto:ir@mediclinic.com)

+44 (0)20 3786 8181

#### **Media queries**

FTI Consulting

Ben Atwell/Ciara Martin - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

**Registered address:** 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK

**Website:** [www.mediclinic.com](http://www.mediclinic.com)

**Corporate broker (United Kingdom):** Morgan Stanley & Co International plc and UBS Investment Bank

**JSE sponsor (South Africa):** Rand Merchant Bank (A division of FirstRand Bank Limited)

**NSX sponsor (Namibia):** Simonis Storm Securities (Pty) Ltd